Piper Sandler analyst Matt O'Brien maintains Humacyte (NASDAQ:HUMA) with a Neutral and lowers the price target from $3.5 to $3.
Piper Sandler Maintains Neutral on Humacyte, Lowers Price Target to $3-Report Released on 9th Nov 2023
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.